Imodium

Loperamide, the active ingredient in Imodium, is an antidiarrheal presented as an oral tablet for oral use. It reduces intestinal motility and fluid secretion, helping to control acute nonspecific diarrhea, traveler’s diarrhea, and chronic diarrhea linked to inflammatory bowel disease.\n\nGNH India supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium is an antidiarrheal medication that acts on the gastrointestinal tract to manage various diarrheal conditions.\n\nAcute nonspecific diarrhea: provides symptomatic relief by slowing intestinal transit and increasing fluid absorption.\nTraveler's diarrhea: helps control symptoms during short‑term travel‑related gastrointestinal upset.\nChronic diarrhea associated with inflammatory bowel disease: assists in reducing stool frequency and improving quality of life.

Adverse reactions may occur with any antidiarrheal therapy.\n\nCommon Side Effects:\n- Constipation: reduced bowel movements or hard stools.\n- Abdominal cramps: mild to moderate discomfort.\n- Nausea: occasional feeling of queasiness.\n- Dizziness: transient light‑headedness.\n\nSerious or Rare Side Effects:\n- Paralytic ileus: severe bowel obstruction requiring medical attention.\n- Cardiac arrhythmias: especially with high doses or drug interactions.\n- Severe allergic reactions: rash, swelling, or difficulty breathing.

Before using Imodium, consider the following safety measures.\n\nDo not use in presence of bacterial infection: may worsen condition.\nAvoid in patients with acute dysentery: risk of toxin retention.\nCaution in hepatic impairment: reduced metabolism may increase exposure.\nLimit use in children under 2 years: safety not established.\nStore at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Loperamide may interact with several medications, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase loperamide plasma levels.\n- CYP2C8 inhibitors (e.g., gemfibrozil): can raise systemic exposure and risk of cardiac effects.\n\nModerate Interactions (Monitor Closely):\n- Other opioids (e.g., codeine): additive central opioid effects.\n- P-glycoprotein inhibitors (e.g., quinidine): may enhance absorption.\n- MAO inhibitors: potential for increased serotonergic activity.